Pharmacology in Sleep Medicine

  • Wallace B. Mendelson
  • Cosmo Caruso
Part of the Current Clinical Practice book series (CCP)


In sleep disorders, as in all of medicine, the prescription of drugs is often an integral component of treatment. This chapter focuses on two general types of sleep medications: drugs that promote sleep and drugs that promote alertness. These have been generally labeled hypnotic-sedatives and central nervous system (CNS) stimulants, respectively. There are numerous classes of agents in each category, and often, numerous specific agents in each class. A few of them are described below, separated into those generally useful in insomnia and those generally useful in states of hypersomnolence such as narcolepsy. More detailed descriptions of the clinical conditions are available elsewhere in this volume, specifically in Chapters 2 and 5.


Obstructive Sleep Apnea Sleep Disturbance Sleep Disorder Sleep Latency Slow Wave Sleep 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Balon R. Sleep terror disorder and insomnia treated with trazodone: a case report. Ann Clin Psychia 1994; 6: 161–163.CrossRefGoogle Scholar
  2. Berry RB, Kouchi K, Bower J, Prosise G, Light RW. Triazolam in patients with obstructive sleep apnea. AJRCCM 1995; 151: 450–454.Google Scholar
  3. Cirignotta F, Mondini S, Zucconi M, Gerardi R, Farolfi A, Lugaresi E. Zolpidempolysomnographic study of the effect of a new hypnotic drug in sleep apnea syndrome. Pharm Biochem Behav 1988; 29: 807–809.CrossRefGoogle Scholar
  4. Croche AF, Lipman RS, Overall JE, Hung W. The effects of stimulant medication on the growth of hyperkinetic children. Pediatrics 1979; 63: 847–850.PubMedGoogle Scholar
  5. Daly DD, Yoss RE. The treatment of narcolepsy with methyl phenylpiperidylacetate: a preliminary report. Proc Mayo Clin 1956; 31: 620–625.Google Scholar
  6. Gross MD. Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desimpramine Pediatrics 1976; 58: 423–431.PubMedGoogle Scholar
  7. Guilleminault C, Carskadon M, Dement WC. On the treatment of rapid eye movement narcolepsy. Arch Neurol 1974; 30: 90–93.PubMedCrossRefGoogle Scholar
  8. Mendelson WB. Clinical neuropharmacology of sleep. Clin Neuropharm 1990; 8: 153–160.Google Scholar
  9. Mendelson WB. Insomnia and related sleep disorders. Psych Clin NAm 1993; 16: 841–851.Google Scholar
  10. Mendelson WB. Subjective vs objective tolerance during chronic administration of triazolam. Clin Drug Invest 1995; 10: 276–279.CrossRefGoogle Scholar
  11. Mendelson WB. Adverse reactions to sedative/hypnotics: three years’ experience. Sleep 1997; 19: 702–706.Google Scholar
  12. Mendelson WB, Jain, B. An assessment of short-acting hypnotics. Drug Safety 1995; 4: 257–270.CrossRefGoogle Scholar
  13. Mendelson WB. Neuropharmacology of sleep induction by benzodiazepines. Crit Rev Neurobiol 1992; 16: 221–232.Google Scholar
  14. Mendelson WB. The use of sedative/hypnotic medication and its correlation with falling down in the hospital. Sleep 1997; 19: 698–701.Google Scholar
  15. Mitler MM, Hajdukovic RM. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 1991; 14: 218–220.PubMedGoogle Scholar
  16. Mohler H, Okada, T. Benzodiazepine receptor: demonstration in the central nervous system. Science 1977; 198: 849–851.PubMedCrossRefGoogle Scholar
  17. Monti JM, Attali P, Monti D, et al. Zolpidem and rebound insomnia: a double blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiat 1994; 27: 166–175.CrossRefGoogle Scholar
  18. Parkes JD, Baraitser M, Marsden CD, Asselman P. Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol Scand 1975; 52: 337–353.PubMedCrossRefGoogle Scholar
  19. Parrino L, Spaggiari MC, Boselli M, Di Giovanni G, Terzano MG. Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology 1994; 116: 389–395.PubMedCrossRefGoogle Scholar
  20. Pascoe PA. Drugs and the sleep-wakefulness continuum. Pharmac Ther 1994; 61: 227–236.CrossRefGoogle Scholar
  21. Saletu B, Anderer P, Brandstatter N, et al. Insomnia in generalized anxiety disorder: polysomnographic, psychometric and clinical investigations before, during and after therapy with a long-vs a short-half-life benzodiazepine (quazepam versus triazolam). Neuropsychobiology 1994; 29: 69–90.PubMedCrossRefGoogle Scholar
  22. Shindler J, Schachter M, Brincat S, Parkes JD. Amphetamine, mazindol and fencamfamin in narcolepsy. Br Med J [Clin Res] 1985; 290: 1167–1170.CrossRefGoogle Scholar
  23. Squires RF, Braestrup C. Benzodiazepine receptors in rat brain. Nature 1977; 266: 732–734.PubMedCrossRefGoogle Scholar

Suggested Readings

  1. Mendelson WB. Clinical neuropharmacology of sleep. Clin Neuropharm 1990; 8: 153–160.Google Scholar
  2. Mendelson WB. Insomnia and related sleep disorders. Psych Clin NAm 1993; 16: 841–851.Google Scholar
  3. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. Sleep 1994; 17: 352–371.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Wallace B. Mendelson
  • Cosmo Caruso

There are no affiliations available

Personalised recommendations